Cost Savings of Avastin Gets Closer Look
Medicare could have saved more than $1 billion and Medicare patients $275 million over two years if doctors treated a serious eye disease with Genentech’s Avastin, instead of the company’s more expensive Lucentis, a government audit found. Read more…
September 7th, 2011
Posted in
Drug